Marker Therapeutics Updates APOLLO Study In Relapsed Lymphoma, Announces $16.1 Mln Private Placement

(RTTNews) - Marker Therapeutics, Inc. (MRKR), Thursday announced an update from its APOLLO study investigating MT-601 in patients with relapsed lymphoma.

The company found that 78 percent of patients achieved objective response rates, with 44.4 percent demonstrating complete response. Moreover, MT-601 was well tolerated with no observation of immune-effector cell associated neurotoxicity syndrome.

Concurrently with the update, Marker also announced the decision to sell around 5.03 million shares at $3.20 a share to raise $16.1 million in private placement.

The company intends to use the proceeds to fund Phase 1 APOLLO study.

Currently, Marker's stock is trading at $3.96, down 1.63 percent on the Nasdaq.